Anti-Human VEGF Recombinant Antibody (FD006) (CAT#: TAB-0346CL)
The anti-VEGF antibody specifically target VEGF which is the most significant positive regulator of angiogenesis. The specific antibody has good biological activity, and it can inhibit vascular endothelial cell proliferation, tumor growth and corneal neovascularization. Thus the antibody can be used for the preparation of antigen-specific drugs and angiogenesis inhibiting drugs.
Specific Inquiry
ELISA
Figure 1 Antigen binding identification of FD006 to bind VEGF.
The binding activity of FD006 by ELISA.
Wang, Q., Yang, J., Tang, K., Luo, L., Wang, L., Tian, L., ... & Lv, M. (2014). Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC biotechnology, 14(1), 17.
PK
Figure 2 Antigen binding identification of FD006 to bind VEGF.
Affinity detection of FD006 by binding kinetics assays.
Wang, Q., Yang, J., Tang, K., Luo, L., Wang, L., Tian, L., ... & Lv, M. (2014). Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC biotechnology, 14(1), 17.
Inhib
Figure 3 Antigen binding identification of FD006 to bind VEGF.
The inhibitory effects of FD006 on VEGF-induced human umbilical vein endothelial cell (HUVEC) proliferation.
Wang, Q., Yang, J., Tang, K., Luo, L., Wang, L., Tian, L., ... & Lv, M. (2014). Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC biotechnology, 14(1), 17.
IHC
Figure 4 Hematoxylin and eosin (HE) staining observation of corneas.
At day 7, corneal neovascularization of various sizes (black arrowhead) were present in the superficial central corneal stroma after alkali burn (×200) and neovascularization containing RBCs in the corneal stroma were indicated with black arrowheads. Cornea stroma exhibited edema and mononuclear inflammatory response. In this plane of section, the corneal epithelium is relatively normal. Bar = 100 μm.
Wang, Q., Yang, J., Tang, K., Luo, L., Wang, L., Tian, L., ... & Lv, M. (2014). Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC biotechnology, 14(1), 17.
WB
Figure 5 The protein expression of neovascularization-related signal molecules in the cornea.
β-actin served as an internal standard. The protein expression of VEGF, MMP-9, VEGFR-1, VEGFR-2 and ICAM-1 in the cornea was significantly weaker in antibody- or dexamethasone- treated samples.
Wang, Q., Yang, J., Tang, K., Luo, L., Wang, L., Tian, L., ... & Lv, M. (2014). Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC biotechnology, 14(1), 17.
Specifications
- Host Species
- Human
- Type
- Human antibody
- Specificity
- Human
- Clone
- FD006
- Applications
- ELISA, PK, Inhib, IHC, WB
- Related Disease
- Colon cancer, tumor, angiogenesis
Applications
- Application Notes
- The VEGF antibody has been reported in applications of Enzyme-linked Immunosorbent Assay, Pharmacokinetic, Inhibition, Immunohistochemistry, Western Blot.
ELISA: ELISA plates were coated with 100 μl/well 0.5 μg/ml VEGF. Bevacizumab or FD006 were diluted (10, 2, 0.4, 0.08, 0.016 and 0.0032 μg/ml) and added for 2 hours' incubation in 37. After three times of washing, the Peroxidase-conjugated affinipure goat anti-human immunoglobulin G (IgG) was added as the secondary antibody for 45 minutes at room temperature. Binding signals were visualized using o-phenylenediamine dihydrochloride (OPD) substrate and the light absorbance was measured with an ELISA reader at 492 nm.
Immunohistochemistry: The rat eyeballs were harvested and fixed in 4% paraformaldehyde. The corneas were excised, embedded in paraffin, cut into 5-μm sections and then prepared for hematoxylin and eosin (H&E) staining. The cornea sections were fixed in acetone. The primary antibodies were VEGF-A, fms-like tyrosine kinase (VEGFR-1, Flt-1) and kinase insert domain receptor (VEGFR-2, Flk-1), matrix metalloproteinase-9 (MMP-9) and intercellular adhesion molecule-1 (ICAM-1). Goat anti-mouse IgG was used as the secondary antibody. Then stained samples were observed and photographed using inverted microscopy.
Western Blot: The rats were euthanized, and the corneas were harvested from the treated eyes. The corneas were dissected and frozen at -70°C, then homogenized in ice-cold RIPA lysis buffer solution. After being centrifuged for 5 minutes at 12,000 revolutions per minute (rpm), the supernatants of the samples were collected. Certain amounts of the protein were separated by electrophoresis on an 8% and 12% sodium dodecyl sulfate-polyacrylamide gel, and transferred to nitrocellulose membranes. Then the membranes were blocked using 5% skim milk in TBST (20 mM Tris, 150 mM NaCl and 0.1% Tween-20) and incubated overnight with primary antibodies: anti-VEGF, MMP-9, VEGF receptor 1, ICAM-1 and VEGF receptor 2. The secondary polyclonal antibodies were used to detect bound primary antibodies: anti-mouse, anti-rabbit, and anti-goat. After washing, an enhanced chemiluminescence solution were used to visualize specific lanes.
Target
- Alternative Names
- VEGF; Vascular endothelial growth factor
Related Resources
Bladder Cancer
Rheumatoid Arthritis
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone FD006"
See other products for "VEGF"
Recombinant Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PABZ-130 | Mouse Anti-VEGF Recombinant Antibody (clone 12) | ELISA, Neut | Mouse IgG |
| HPAB-AP213-YC | Human Anti-VEGF Recombinant Antibody (HPAB-AP213-YC) | ELISA | Human IgG |
| HPAB-J0264-YC | Human Anti-VEGF Recombinant Antibody (clone G12) | ELISA | Human IgG |
| HPAB-J0265-YC | Human Anti-VEGF Recombinant Antibody (clone E9) | ELISA | Human IgG |
| HPAB-J0269-YC | Mouse Anti-VEGF Recombinant Antibody (clone EGF165) | ELISA, WB | Mouse IgG |
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PFBZ-130 | Mouse Anti-VEGF Recombinant Antibody (clone 12); Fab Fragment | ELISA, Neut | Mouse Fab |
| PFBW-130 | Mouse Anti-VEGF Recombinant Antibody (clone A4.6.1); Fab Fragment | Neut, ELISA | Mouse Fab |
| PFBC-131 | Human Anti-VEGF Recombinant Antibody (clone B20-4); Fab Fragment | ELISA, Neut, Block | Human Fab |
| HPAB-0746LY-F(E) | Human Anti-VEGF Recombinant Antibody; Fab Fragment (HPAB-0746LY-F(E)) | ELISA | Humanized Fab |
| HPAB-AP213-YC-F(E) | Human Anti-VEGF Recombinant Antibody; Fab Fragment (HPAB-AP213-YC-F(E)) | ELISA | Human Fab |
scFv Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PSBZ-130 | Mouse Anti-VEGF Recombinant Antibody (clone 12); scFv Fragment | ELISA, Neut | Mouse scFv |
| HPAB-2820LY-S(P) | Human Anti-VEGF Recombinant Antibody; scFv Fragment (HPAB-2820LY-S(P)) | ELISA, WB | Humanized scfv |
| HPAB-J0264-YC-S(P) | Human Anti-VEGF Recombinant Antibody (clone G12); scFv Fragment | ELISA, Neut | Human scFv |
| HPAB-J0265-YC-S(P) | Human Anti-VEGF Recombinant Antibody (clone E9); scFv Fragment | ELISA, Neut | Human scFv |
| HPAB-J0269-YC-S(P) | Mouse Anti-VEGF Recombinant Antibody (clone EGF165); scFv Fragment | ELISA, WB | Mouse scFv |
Mouse Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-285CQ | Mouse Anti-VEGF Recombinant Antibody (TAB-285CQ) | ELISA, WB, Inhib | Mouse IgG1 |
| TAB-287CQ | Mouse Anti-VEGF Recombinant Antibody (TAB-287CQ) | ELISA | Mouse IgG1, κ |
| TAB-290CQ | Anti-Human VEGF Recombinant Antibody | ELISA, WB, Neut | |
| TAB-285CQ-S(P) | Mouse Anti-VEGF Recombinant Antibody; scFv Fragment (TAB-285CQ-S(P)) | ELISA, WB, Neut | Mouse scFv |
| TAB-287CQ-S(P) | Mouse Anti-VEGF Recombinant Antibody; scFv Fragment (TAB-287CQ-S(P)) | ELISA, WB, IHC, Block | Mouse scFv |
Humanized Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-289CQ | Human Anti-VEGF Recombinant Antibody (TAB-289CQ) | ELISA | Human IgG1, κ |
| TAB-293CQ | Anti-Human VEGF Recombinant Antibody (HAB1) | WB | Humanized antibody |
| TAB-294CQ | Anti-Human VEGF Recombinant Antibody (hAB2) | ELISA, Inhib | Humanized antibody |
| TAB-295CQ | Anti-Human VEGF Recombinant Antibody (hAB3) | ELISA, Inhib | Humanized antibody |
| TAB-293CQ-S(P) | Anti-Human VEGF Recombinant Antibody scFv Fragment (HAB1) | ELISA, Inhib | Humanized antibody |
Chimeric Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-301CQ | Human Anti-VEGF Recombinant Antibody (TAB-301CQ) | ELISA, FC, IHC, WB | Chimeric (Mouse/Human) IgG1, κ |
| TAB-288CQ-F(E) | Human Anti-VEGF Recombinant Antibody; Fab Fragment (TAB-288CQ-F(E)) | ELISA, WB, IHC, Block | Chimeric (Mouse/Human) Fab |
| TAB-301CQ-F(E) | Human Anti-VEGF Recombinant Antibody; Fab Fragment (TAB-301CQ-F(E)) | ELISA, FC, IHC, WB | Chimeric (Mouse/Human) Fab |
| PABX-185 | Recombinant Human Anti-VEGF Antibody (Fab-12) | ELISA, FuncS | IgG |
| PABX-185-F (E) | Recombinant Mouse Anti-VEGF Antibody Fab Fragment (Fab-12) | ELISA, FuncS | Fab |
Human Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-409CQ | Human Anti-VEGF Recombinant Antibody (TAB-409CQ) | ELISA | Human IgG |
| TAB-409CQ-F(E) | Human Anti-VEGF Recombinant Antibody; Fab Fragment (TAB-409CQ-F(E)) | ELISA | Human Fab |
| TAB-410CQ-F(E) | Human Anti-VEGF Recombinant Antibody; Fab Fragment (TAB-410CQ-F(E)) | ELISA | Human Fab |
| PABX-186 | Human Anti-VEGF Recombinant Antibody (PABX-186) | WB, ELISA, FuncS | Human IgG |
| PABX-186-F (E) | Human Anti-VEGF Recombinant Antibody; Fab Fragment (PABX-186-F (E)) | WB, ELISA, FuncS | Human Fab |
Fc Glycosylation
| CAT | Product Name | Application | Type |
|---|---|---|---|
| Gly-096LC | Recombinant Anti-Human VEGF Antibody (Fc glycosylation) | ELISA | Humanized antibody |
| Gly-143LC | Recombinant Anti-Human VEGF Antibody (Fc glycosylation) | ELISA | Humanized antibody |
Deglycosylated Antibody (Non-glycosylated IgGs)
| CAT | Product Name | Application | Type |
|---|---|---|---|
| Gly-179LC | Recombinant Anti-Human VEGF Antibody (Non-glycosylated) | ELISA | Human antibody |
Rabbit Monoclonal Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOR-4485 | Rabbit Anti-VEGF Recombinant Antibody (clone SI581DS) | ELISA | Rabbit IgG |
Single-domain Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-J0267-YC | Recombinant Camelid Anti-VEGF Single Domain Antibody (V9) | ELISA, Neut | Camelid VHH |
| HPAB-J0268-YC | Recombinant Camelid Anti-VEGF Single Domain Antibody (V93) | ELISA, Neut | Camelid VHH |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for TAB-0346CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.